[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337722-105":59,"doc-detail-337722-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","synergy-of-egfr-and-aurka-inhibitors-in-kras-mutated-non-small-cell-lung-cancers","Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non-small Cell Lung Cancers","","Most oncogenic driver mutations in non–small cell lung cancer (NSCLC) activate EGFR or KRAS, and targeted small-molecule inhibitors often work better when combined with chemotherapy or other targeted agents. In EGFR-mut NSCLC, combining EGFR and Aurora-A kinase (AURKA) inhibition has shown clinical promise. This study evaluates dual EGFR and AURKA inhibition in KRAS-mut NSCLC models, showing synergy between erlotinib and alisertib in vitro and reduced xenograft growth in vivo. Mechanistic analyses indicate stronger suppression of EGFR pathway effectors after brief or extended dosing, with increased cell death.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/synergy-of-egfr-and-aurka-inhibitors-in-kras-mutated-non-small-cell-lung-cancers/337722/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/synergy-of-egfr-and-aurka-inhibitors-in-kras-mutated-non-small-cell-lung-cancers/337722.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the study’s main focus regarding NSCLC?","Question",{"text":113,"@type":114},"The study evaluates dual inhibition of EGFR and AURKA in KRAS-mutated NSCLC models, testing whether the two-target approach produces synergistic anti-tumor effects.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do erlotinib and alisertib work together in vitro?",{"text":118,"@type":114},"The combination of erlotinib (EGFR inhibitor) and alisertib (AURKA inhibitor) synergistically reduces cell viability and clonogenic capacity in vitro.",{"name":120,"@type":111,"acceptedAnswer":121},"Does the drug combination show benefits in vivo?",{"text":122,"@type":114},"Yes. The erlotinib–alisertib combination synergistically reduces xenograft tumor growth in vivo, and pathway analyses show improved suppression of EGFR signaling compared with single agents.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},337722,1790138497,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-23-0482](https://doi.org/10.1158/2767-9764.CRC-23-0482)   \nSynergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers  \nTetyana Bagnyukova1 , Brian L. Egleston1 , Valerii A. Pavlov1 , 2 , Ilya G. Serebriiskii1 , 3 , Erica A. Golemis1 , 4 , and Hossein Borghaei1 , 5  \nOPEN  \nACCESS  \nCheck for updates  \nABSTRACT  \nThe most common oncogenic driver mutations for non–small cell lung cancer (NSCLC) activate EGFR or KRAS. Clinical trials exploring treatments for EGFR-or KRAS-mutated (EGFRmut or KRASmut) cancers have focused on small-molecule inhibitors targeting the driver mutations. Typically, these inhibitors perform more effectively based on combination with either chemotherapies, or other targeted therapies. For EGFRmut NSCLC, a combination of inhibitors of EGFR and Aurora-A kinase (AURKA), an oncogene commonly overexpressed in solid tumors, has shown promising activity in clinical trials. Interestingly, a number of recent studies have indicated that EGFR activity supports overall viability of tumors lacking EGFR mutations, and AURKA expression is abundant in KRASmut cell lines. In this study, we have evaluated dual inhibition of EGFR and AURKAin KRASmut NSCLC models. These data demonstrate synergy between the EGFR inhibitor erlotinib and the AURKA inhibitor alisertib in reducing cell viability and clonogenic capacity in vitro, associated with reduced  \nactivity of EGFR pathway effectors, accumulation of enhanced aneuploid cell populations, and elevated cell death. Importantly, the erlotinib-alisertib combination also synergistically reduces xenograft growth in vivo. Analysis of signaling pathways demonstrated that the combination of erlotiniband alisertib was more effective than single-agent treatments at reducing activity of EGFR and pathway effectors following either brief or extended administration of the drugs. In sum, this study indicates value of inhibiting EGFR inKRASmut NSCLC, and suggests the specific value of dual inhibition ofAURKA and EGFR in these tumors.  \nSignificance: The introduction of specific KRAS G12C inhibitors to the clinical practice in lung cancer has opened up opportunities that did not exist before. However, G12C alterations are only a subtype of all KRAS mutations observed. Given the high expression of AURKA in KRASmut NSCLC, our study could point to a potential therapeutic option for this subgroup of patients.  \nIntroduction  \nIn 2022, there were approximately 237,000 new diagnoses of lung cancer, and 130,000 deaths from this disease, in the United States (1) . Although abysmal, these numbers nevertheless reflect an improvement in the treatability of lung cancer, based on increasing knowledge of the biology of this disease, and the development of new therapeutic strategies (2). The most common form of lung cancer, non–small cell lung cancer (NSCLC), falls into two primary subtypes: lung adenocarcinoma (LUAD) and lung squamous cell carcinoma. For the more common subtype, LUAD, the most common driver mutations are activation of  \n1 Program in Cell Signaling and Metastasis, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 2 Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region, Russian Federation. 3 Kazan Federal University, Kazan, Russian Federation.  \n4 Department of Cancer and Cellular Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania. 5 Division of Thoracic Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.  \nCorresponding Author: Hossein Borghaei, Fox Chase Cancer Center, 333 Cottman  \nAve, Philadelphia, PA 19111 . E-mail: [hossein.borghaei@fccc.edu](hossein.borghaei@fccc.edu)  \n[doi:](doi: 10.1158/2767-9764.CRC-23-0482)[ 10.1158/2767-9764.CRC-23-0482](doi: 10.1158/2767-9764.CRC-23-0482)  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4 .0) license.  \n© 2024 The Authors; Published by t","cbCaiv10Bj1Bh4Ih","https://ap.wps.com/l/cbCaiv10Bj1Bh4Ih","pdf",11456258,13,"English","# Abstract\n# Significance\n# Introduction","[{\"question\":\"What is the study’s main focus regarding NSCLC?\",\"answer\":\"The study evaluates dual inhibition of EGFR and AURKA in KRAS-mutated NSCLC models, testing whether the two-target approach produces synergistic anti-tumor effects.\"},{\"question\":\"How do erlotinib and alisertib work together in vitro?\",\"answer\":\"The combination of erlotinib (EGFR inhibitor) and alisertib (AURKA inhibitor) synergistically reduces cell viability and clonogenic capacity in vitro.\"},{\"question\":\"Does the drug combination show benefits in vivo?\",\"answer\":\"Yes. The erlotinib–alisertib combination synergistically reduces xenograft tumor growth in vivo, and pathway analyses show improved suppression of EGFR signaling compared with single agents.\"}]","Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non-small Cell Lung Cancers | PDF",1790020350,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ae8c019d564aee827b0c8a051da0f47.webp",983,1263,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99fc0c63bd97193156d8f1993e1696e3.webp",982,1262,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/808410a3eb055991fb8499a706ea4d9c.webp",981,1261,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/759899ffaadd6de017e9b2f3f9ca230a.webp",980,1259]